BRAF V600E Clinical Trials

12 clinical trials for BRAF V600E across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — RECRUITING · PHASE1
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — RECRUITING · PHASE2
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy — RECRUITING
• ENCOrafenib With Binimetinib in bRAF NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. — COMPLETED · PHASE2
• Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer — COMPLETED · PHASE2
• Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma — COMPLETED · PHASE2
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG — TERMINATED · PHASE2
• A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. — TERMINATED · PHASE2
• Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology. — OTHER
• A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas — TERMINATED
• Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation — OTHER · PHASE2

Refine this search